


What is claimed is:

1. A method for treating a cancer in a subject, comprising administering to the subject an effective amount of a first anti-cancer agent and an effective amount of at least one second anti-cancer agent, wherein the first anti-cancer agent is represented by Formula (I):



or a pharmaceutically acceptable salt thereof; and wherein the at least one second anti-cancer agent is selected from the group consisting of a BH3 mimetic and a DNA demethylating agent, or a combination thereof.

2. The method of claim 1, wherein the cancer is a hematological malignancy.
3. The method of claim 1 or 2, wherein the cancer is selected from the group consisting of a leukemia and a lymphoma.
4. The method of any one of claims 1 to 3, wherein the cancer is selected from the group consisting of acute myeloid leukemia (AML), multiple myeloma, B-prolymphocytic leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, follicular lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, T-cell lymphoma, acute monocytic leukemia, B-cell lymphoma, diffuse mixed cell lymphoma, myelodysplastic syndrome, primary effusion lymphoma, erythroleukemia, chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), double hit diffuse large B cell lymphoma, triple hit diffuse large B cell lymphoma, blastic plasmacytoid dendritic cell neoplasm, and small lymphocytic lymphoma (SLL).
5. The method of any one of claims 1 to 4, wherein the cancer is selected from the group consisting of diffuse large B cell lymphoma, chemotherapy-resistant acute myeloid leukemia, and cytarabine-resistant acute myeloid leukemia.

6. The method of any one of claims 1 to 4, wherein the cancer is selected from acute myeloid leukemia, multiple myeloma, B-prolymphocytic leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, follicular lymphoma, diffuse large B cell lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, and T-cell lymphoma.
7. The method of any one of claims 1 to 4, wherein the cancer is selected from acute myeloid leukemia, multiple myeloma, B-prolymphocytic leukemia, non-Hodgkin's lymphoma, diffuse large B cell lymphoma, anaplastic large cell lymphoma, and mantle cell lymphoma.
8. The method of any one of claims 1 to 4, wherein the cancer is selected from acute myeloid leukemia and diffuse large B-cell lymphoma.
9. The method of any one of claims 1 to 8, wherein the at least one second anti-cancer agent is a combination of a BH3 mimetic and a DNA demethylating agent.
10. The method of any one of claims 1 to 8, wherein the at least one second anti-cancer agent is a BH3 mimetic.
11. The method of claim 9 or 10, wherein the BH3 mimetic is selected from the group consisting of venetoclax, BGB-11417, navitoclax (ABT-263), LP-108, S55746, S65487, AT-101, APG-1252, obatoclax, APG2575, and BCL-201.
12. The method of any one of claims 9 to 11, wherein the BH3 mimetic is venetoclax.
13. The method of any one of claims 1 to 8, wherein the at least one second anti-cancer agent is a DNA demethylating agent.
14. The method of claim 9 or 13, wherein the DNA demethylating agent is a cytidine analogue.
15. The method of any one of claims 9, 13, and 14, wherein the DNA demethylating agent is selected from the group consisting of 5-azacitidine (azacitidine), 5-aza-2'-deoxycytidine

(decitabine), 1- β -D-arabinofuranosylcytosine (cytarabine or ara-C), pseudoiso-cytidine (psi ICR), 5-fluoro-2'-deoxycytidine (FCdR), 2'-deoxy-2',2'-difluorocytidine (gemcitabine), 5-aza-2'-deoxy-2',2'-difluorocytidine; 5-aza-2'-deoxy-2'-fluorocytidine; 1- β -D-ribofuranosyl-2(1H)-pyrimidinone (Zebularine), 2',3'-dideoxy-5-fluoro-3'-thiacytidine (emtriva), 2'-cyclocytidine (Ancitabine), 1- β -D-arabinofuranosyl-5-azacytosine (fazarabine or ara-AC), 6-azacitidine (6-aza-CR), 5,6-dihydro-5-azacitidine (dH-aza-CR), N4 pentyloxy-carbonyl-5'-deoxy-5-fluorocytidine (capecitabine), N4 octadecyl-cytarabine, and elaidic acid cytarabine.

16. The method of any one of claims 9 and 13 to 15, wherein the DNA demethylating agent is selected from the group consisting of azacitidine and cytarabine.

17. The method of any one of claims 9 and 13 to 16, wherein the DNA demethylating agent is azacitidine.


18. The method of any one of claims 1 to 17, wherein the first anti-cancer agent and the at least one second anti-cancer agent are administered simultaneously in the same or different formulations.

19. The method of any one of claims 1 to 18, wherein the first anti-cancer agent and the at least one second anti-cancer agent are administered sequentially.

20. The method of any one of claims 1 to 19, wherein the first anti-cancer agent is the tris(hydroxymethyl)aminomethane salt of the compound of Formula (I).

21. The method of any one of claims 1 to 19, wherein the first anti-cancer agent is the sodium salt of the compound of Formula (I).

22. A pharmaceutical composition comprising a first anti-cancer agent and at least one second anti-cancer agent, wherein the pharmaceutical composition additionally comprises an excipient, wherein the first anti-cancer agent is represented by Formula (I):



or a pharmaceutically acceptable salt thereof; and wherein the at least one second anti-cancer agent is selected from the group consisting of a BH3 mimetic and a DNA demethylating agent, or a combination thereof.

23. The pharmaceutical composition of claim 22, wherein the at least one second anti-cancer agent is a combination of a BH3 mimetic and a DNA demethylating agent.

24. The pharmaceutical composition of claim 22, wherein the at least one second anti-cancer agent is a BH3 mimetic.

25. The pharmaceutical composition of any one of claims 22 to 24, wherein the BH3 mimetic is selected from the group consisting of venetoclax, BGB-11417, navitoclax (ABT-263), LP-108, S55746, S65487, AT-101, APG-1252, obatoclax, APG2575, and BCL-201.

26. The pharmaceutical composition of any one of claims 22 to 25, wherein the BH3 mimetic is ventoclax.

27. The pharmaceutical composition of claim 22, wherein the at least one second anti-cancer agent is a DNA demethylating agent.

28. The pharmaceutical composition of claim 22 and 27, wherein the DNA demethylating agent is a cytidine analogue.

29. The pharmaceutical composition of any one of claims 22, 27, and 28, wherein the DNA demethylating agent is selected from the group consisting of 5-azacitidine (azacitidine), 5-aza-2'-deoxycytidine (decitabine), 1-β-D-arabinofuranosylcytosine (cytarabine or ara-C), pseudoisocytidine (psi ICR), 5-fluoro-2'-deoxycytidine (FCdR), 2'-deoxy-2',2'-difluorocytidine

(gemcitabine), 5-aza-2'-deoxy-2',2'-difluorocytidine; 5-aza-2'-deoxy-2'-fluorocytidine; 1-β-D-ribofuranosyl-2(1H)-pyrimidinone (Zebularine), 2',3'-dideoxy-5-fluoro-3'-thiacytidine (emtriva), 2'-cyclocytidine (Ancitabine), 1-β-D-arabinofuranosyl-5-azacytosine (fazarabine or ara-AC), 6-azacitidine (6-aza-CR), 5,6-dihydro-5-azacitidine (dH-aza-CR), N4 pentyloxy-carbonyl-5'-deoxy-5-fluorocytidine (capecitabine), N4 octadecyl-cytarabine, and elaidic acid cytarabine.

30. The pharmaceutical composition of any one of claims 22 and 27 to 29, wherein the DNA demethylating agent is selected from the group consisting of azacitidine and cytarabine.

31. The pharmaceutical composition of any one of claims 22 and 27 to 30, wherein the DNA demethylating agent is azacitidine.

32. The pharmaceutical composition of any one of claims 22 to 31, wherein the first anti-cancer agent is the tris(hydroxymethyl)aminomethane salt of the compound of Formula (I).

33. The pharmaceutical composition of any one of claims 22 to 31, wherein the first anti-cancer agent is the sodium salt of the compound of Formula (I).